On today’s podcast, we go beyond the headlines to explore what’s driving the latest wave of GLP-1 momentum, why this represents a lasting shift rather than just another healthcare trend, the biggest misconception retailers still have about how these drugs are changing consumer behavior, and which parts of the retail playbook need to be rewritten as consumers change how they eat, shop, and live. Tune in for a discussion featuring Vice President of Content and host Suzy Davidkhanian, along with Senior Analysts Rajiv Leventhal and Rachel Wolff.
OpenAI's latest ChatGPT health advice lawsuit could force stronger AI medical guardrails.
Novo's GLP-1 ad lawsuit against Lilly could redefine the standards for comparative drug advertising in a market projected to reach $200 billion.
Its no-subscription Cirqa band joins a crowded field where AI features, not screens, set products apart.
With no confirmed source for the cyclospora outbreak, clear communication may be key to winning diners back.
Pharma marketers should match the influence of clinical proof, cost details, and patient voices to the values of each audience.
The next phase of GLP-1 marketing competition may hinge on whether brands convince consumers to stay on treatment or build habits that last after stopping them.
Affordability drives food purchases more than health, but brands that pair value with nutrition stand to gain.
Reaching patients through insurers and providers could unlock wearable adoption among higher-need cohorts and strengthen long-term loyalty.
Younger adults mostly use these health features, but older adults' faster uptake points to untapped demand.
Its acquisition of a psychedelic drug developer adds credibility to the field, but commercialization will hinge on reimbursement and supervised care.
The decline mostly reflects pullbacks in diabetes and blood disorder advertising, not a broad retreat from linear TV advertising.
Healthcare providers and marketers in the UK should help teens build healthier habits ahead of social media bans and curfews.
Its prediction market now covers FDA approvals and trials, adding a new signal that could sway biotech valuations and trial participation.
Wegovy pill's lead over Foundayo signals drug marketers need to build consumer and healthcare provider brand awareness before launch.
Health advice is the No. 1 reason consumers turn to AI for guidance, putting greater pressure on physicians to correct inaccurate information.
Legal cases over Tylenol use during pregnancy and autism pull Kenvue and retailers back into a fight that could test consumer trust.
Biogen's early stage therapy will prompt health systems and providers to rethink how they care for Alzheimer's patients remotely.
Ingredient removals and limited public details could shape consumer perceptions before investigators reach conclusions.
Almost half (44%) use AI, but limited training and low confidence keep most nurses double-checking outputs, reducing time savings from the tech.